Medical/Pharmaceuticals

Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...

2021-12-03 16:23 2581

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...

2021-12-03 10:13 2905

Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH

SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in theUSA for the RISE study, a Phase IIa clinical trial of HPG18...

2021-12-02 23:00 2184

MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102

GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a ...

2021-12-02 22:00 2347

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered ...

2021-12-02 21:58 2896

Rayence's Low-Dose Detector "GreenON" Receives Critical Acclaim at RSNA 2021

SEOUL, South Korea, Dec. 2, 2021 /PRNewswire/ -- Rayence(www.rayence.com ) reported that its low-dose detectors "GreenON" received critical acclaim at the RSNA(Radiological Society ofNorth America) 2021.

2021-12-02 21:30 2986

DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator's Chief Operating Officer

CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator inChina ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Off...

2021-12-02 16:00 2534

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic64...

2021-12-01 21:57 2634

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refrac...

2021-12-01 21:54 2907

U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

ADELAIDE, Australia, Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 development progr...

2021-12-01 19:00 3549

Great Bay Bio Completes a Near USD 10M Series A Fundraising

HONG KONG, Dec. 1, 2021 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of its nearUSD 10M series A fundraising led by Proxima Ventures. The round was oversubscribed and upsized with participation by many new and existing institutional ...

2021-12-01 15:00 4076

Binhai New Area to spearhead China's medical industry development

TIANJIN, China, Nov. 30, 2021 /PRNewswire/ -- Here's a news report from chinadaily.com.cn: By 2025, the Binhai New Area in North China's Tianjin municipality will cultivate industry clusters worth tens of billions of yuan that are dedicated to pharmaceuticals, biotech, medical devices, diagnosti...

2021-12-01 11:20 2538

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-...

2021-12-01 08:00 2162

Standigm signs MOU with Institut Pasteur Korea for AI-based drug discovery research on infectious disease

SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding ("MOU") with Institut Pasteur Korea ("IPK"), the infectious disease-focused research...

2021-11-30 21:30 2538

ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the N...

2021-11-30 13:00 2652

Q-Sera enters exclusive agreement with Terumo Corporation for RAPClot™ rapid serum blood collection tube technology in Japan

MELBOURNE, Australia, Nov. 29, 2021 /PRNewswire/ -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced a partnership with Terumo Corporation, the leading Japanese medical device company, which will see its patent protected RAPClot™ rapid serum tube technology manufactured and u...

2021-11-30 01:00 2788

GBM AGILE Opens to Paxalisib in Canada

SYDNEY, Nov. 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre inToronto, Ontario. Thi...

2021-11-29 22:05 3978

ClariPi to Showcase its AI Medical Imaging Solutions at RSNA 2021

SEOUL, South Korea, Nov. 29, 2021 /PRNewswire/ -- ClariPi, a leading AI medical imaging company, is presenting its AI-powered low-dose CT denoising solution, ClariCT.AI along with new innovative AI imaging solutions at RSNA 2021. ClariCT.AI is a vendor-agnostic software solution offering a superb...

2021-11-29 22:00 2347

United Imaging Blazes a Trail, Helping Customers "Future Proof"

HOUSTON, Nov. 29, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, presents at this year's RSNA a symposium that's accessible both in person and via live-stream to registered attendees, entitled: Rethinking How Radiology Can Work In Prac...

2021-11-29 22:00 2190

OriCiro Genomics Launches New enzymatic DNA synthesis tool for commonly used vectors

TOKYO, Nov. 29, 2021 /PRNewswire/ -- OriCiro Genomics Inc., a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the launch of OriCiro® Cell-Free Switching system. In the biological sciences, cell-based clon...

2021-11-29 22:00 2458
1 ... 255256257258259260261 ... 264